Progression to Insulin Therapy in Patients With Type 2 Diabetes According to Cardiorespiratory Fitness, Body Mass Index, and Statin Therapy.

[1]  Eric L. Johnson,et al.  10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. , 2022, Diabetes care.

[2]  R. Gabbay,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). , 2022, Diabetes care.

[3]  X. Sui,et al.  Cardiorespiratory Fitness and Mortality Risk Across the Spectra of Age, Race, and Sex. , 2022, Journal of the American College of Cardiology.

[4]  M. Matheny,et al.  Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. , 2022, Diabetes care.

[5]  E. Halm,et al.  Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study. , 2021, JAMA internal medicine.

[6]  E. Ashley,et al.  The genetics of human performance , 2021, Nature Reviews Genetics.

[7]  Abigail Silva,et al.  Comparison of All-Cause Mortality Rates and Inequities Between Black and White Populations Across the 30 Most Populous US Cities , 2021, JAMA network open.

[8]  P. Wilson,et al.  Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older. , 2020, JAMA.

[9]  Sunyoung Cho,et al.  Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study , 2020, Cardiovascular Diabetology.

[10]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[11]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[12]  Eric L. Johnson,et al.  Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018 , 2018, Annals of Internal Medicine.

[13]  B. Franklin,et al.  Cardiorespiratory Fitness and Health Outcomes: A Call to Standardize Fitness Categories , 2017, Mayo Clinic proceedings.

[14]  X. Sui,et al.  Cardiorespiratory Fitness and Incidence of Type 2 Diabetes in United States Veterans on Statin Therapy. , 2017, The American journal of medicine.

[15]  G. Corrao,et al.  Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[16]  J. Hawley,et al.  Update on the effects of physical activity on insulin sensitivity in humans , 2017, BMJ Open Sport & Exercise Medicine.

[17]  E. Boyko,et al.  Validation of methods for assessing cardiovascular disease using electronic health data in a cohort of Veterans with diabetes , 2016, Pharmacoepidemiology and drug safety.

[18]  J. Boucher,et al.  Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. , 2015, Journal of the Academy of Nutrition and Dietetics.

[19]  P. Lee,et al.  Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes , 2014, Diabetology & Metabolic Syndrome.

[20]  D. Panagiotakos,et al.  Statins modulate the mortality risk associated with obesity and cardiorespiratory fitness in diabetics. , 2013, The Journal of clinical endocrinology and metabolism.

[21]  D. Panagiotakos,et al.  Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study , 2013, The Lancet.

[22]  Demosthenes B Panagiotakos,et al.  Exercise capacity and mortality in older men: a 20-year follow-up study. , 2010, Circulation.

[23]  M. Quon,et al.  Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. , 2010, Journal of the American College of Cardiology.

[24]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[25]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.

[26]  A. King,et al.  Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. , 2007, Medicine and science in sports and exercise.

[27]  R. Karas,et al.  Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. , 2007, Journal of the American College of Cardiology.

[28]  D. Berlowitz,et al.  Risk-Adjusted Mortality Rates as a Potential Outcome Indicator for Outpatient Quality Assessments , 2002, Medical care.

[29]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[30]  J. Feussner,et al.  Reinventing VA health care: systematizing quality improvement and quality innovation. , 2000, Medical care.

[31]  P. Eggers,et al.  Effects of race and income on mortality and use of services among Medicare beneficiaries. , 1996, The New England journal of medicine.